HEALTH● LOW1h ago · Oct 24, 2026, 2:30 AM
Moderna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trial
news4sanantonio.com · United States · global
A personalized mRNA melanoma vaccine developed by Moderna and Merck has demonstrated a reduction in relapse risk in a late-stage trial. This represents a significant advancement in medical research and cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapUnited States and nearby eventsMore from United StatesLatest stories and threat level
More from United States
POLITICS1h agoTrump Tells Florida of Plans for united states to Topple Cuban Communist Regimebreitbart.com · United StatesPOLITICS7h agoMilei received a Trump official and there was new support: "Argentina is betting on reforms and the United States accompanies with investment"ClarínCONFLICTBREAKING7h agoSuspicions grow of a new wave of United States attacks against Iran in the coming daysClarínWORLD20h agoDali chief engineer blocked from entering United Stateswbaltv.com · United States
More in Health
HEALTH17m agoEBOLA: Genomics links Nigeria’s case to Kenya index case – PateVanguard NigeriaHEALTH33m agoHow is Kerala planning to prevent child deaths linked to malnutrition and neglect? ExplainedThe HinduHEALTH1h agoModerna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trialnebraska.tv · United StatesHEALTH1h agoModerna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trialbakersfieldnow.com · United States